Cite
The immune-related adverse events paradox in locally advanced or metastatic urothelial cancer after atezolizumab immunotherapy: analysis of individual patient data from IMvigor210 and IMvigor211 trials.
MLA
Robesti, Daniele, et al. “The Immune-Related Adverse Events Paradox in Locally Advanced or Metastatic Urothelial Cancer after Atezolizumab Immunotherapy: Analysis of Individual Patient Data from IMvigor210 and IMvigor211 Trials.” BJU International, vol. 133, no. 2, Feb. 2024, pp. 158–68. EBSCOhost, https://doi.org/10.1111/bju.16121.
APA
Robesti, D., Nocera, L., Belladelli, F., Schultz, J. G., Fallara, G., Marandino, L., Raggi, D., Montorsi, F., Msaouel, P., Necchi, A., & Martini, A. (2024). The immune-related adverse events paradox in locally advanced or metastatic urothelial cancer after atezolizumab immunotherapy: analysis of individual patient data from IMvigor210 and IMvigor211 trials. BJU International, 133(2), 158–168. https://doi.org/10.1111/bju.16121
Chicago
Robesti, Daniele, Luigi Nocera, Federico Belladelli, Julianne G Schultz, Giuseppe Fallara, Laura Marandino, Daniele Raggi, et al. 2024. “The Immune-Related Adverse Events Paradox in Locally Advanced or Metastatic Urothelial Cancer after Atezolizumab Immunotherapy: Analysis of Individual Patient Data from IMvigor210 and IMvigor211 Trials.” BJU International 133 (2): 158–68. doi:10.1111/bju.16121.